Jeanette Weidner - 29 Oct 2026 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
30 Oct 2026, 17:10:48 UTC
Prior SEC filing
30 Oct 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jeanette Weidner
Filing notes and source

Key filing fact

Jeanette Weidner filed Form 4 for Gain Therapeutics, Inc. (GANX) on 30 Oct 2026.

Key facts

  • This page summarizes Jeanette Weidner's Form 4 filing for Gain Therapeutics, Inc. (GANX).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 30 Oct 2026, 17:10.

Change

  • Previous filing in this sequence was filed on 30 Oct 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002158946 Primary reporting owner

Weidner Jeanette

Relationship
Principal Accounting Officer and Principal Financial Officer
Address
C/O GAIN THERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 220, BETHESDA
Signature
/s/ Jeanette Weidner
Signature date
30 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GANX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+130,000
Change %
Price
$0.000000*
Shares after
130,000
Date
29 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
130,000
Exercise price
$1.19
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying the Option shall vest as to 25% on October 29, 2027, and the remainder shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

SEC remarks

Principal Accounting Officer and Principal Financial Officer

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .